SEC Form 4 · accession 0001209191-19-007775
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Feb 4, 2019
Accepted (ET)
Feb 6, 2019 · 4:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 4, 2019 | M | 4,250 | $109.41 | A | 51,002 | D | |
| Common Stock | Feb 4, 2019 | M | 2,155 | $91.05 | A | 53,157 | D | |
| Common Stock | Feb 4, 2019 | M | 1,554 | $86.52 | A | 54,711 | D | |
| Common StockF2,F3 | Feb 4, 2019 | S | 1,400 | $184.81 | D | 53,311 | D | |
| Common StockF3,F4 | Feb 4, 2019 | S | 12,565 | $186.10 | D | 40,746 | D | |
| Common StockF3,F5 | Feb 4, 2019 | S | 4,044 | $186.84 | D | 36,702 | D | |
| Common StockF3,F6 | Feb 4, 2019 | S | 300 | $188.07 | D | 36,402 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $109.14 | Feb 4, 2019 | M | 4,250 | A | — | Feb 2, 2025 | Common Stock | 4,250 | 0 | D |
| Stock Option (Right to Buy)F8 | $91.05 | Feb 4, 2019 | M | 2,155 | A | — | Feb 1, 2026 | Common Stock | 2,155 | 8,621 | D |
| Stock Option (Right to Buy)F9 | $86.52 | Feb 4, 2019 | M | 1,554 | A | — | Feb 2, 2027 | Common Stock | 1,554 | 12,426 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $184.81(range $184.50 to $185.50).
- F3Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $186.10 (range $185.55 to $186.50).
- F5Open market sales reported on this line occurred at a weighted average price of $186.84 (range $186.52 to $187.33).
- F6Open market sales reported on this line occurred at a weighted average price of $188.07(range $187.51 to $188.35).
- F7The option vests in 16 quarterly installments from 02/03/2015.
- F8The option vests in 16 quarterly installments from 02/02/2016.
- F9The option vests in 16 quarterly installments from 02/03/2017.